Figure 2
Clinical decisions in patients with left atrial appendage thrombus despite chronic use of: apixaban (A), dabigatran (B), edoxaban (C), and rivaroxaban (D). DAPT, dual antiplatelet therapy; LMWH, low-molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; UFH, unfractionated heparin; VKA, vitamin K antagonist.

Clinical decisions in patients with left atrial appendage thrombus despite chronic use of: apixaban (A), dabigatran (B), edoxaban (C), and rivaroxaban (D). DAPT, dual antiplatelet therapy; LMWH, low-molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; UFH, unfractionated heparin; VKA, vitamin K antagonist.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close